OPKO Health rallies on positive Phase 2 diabetes and obesity trial results
Thursday, 21 March 2019 OPKO Health Inc (NASDAQ:OPK) climbed Thursday after announcing positive topline results from a Phase 2 dose escalation trial of a treatment for Type 2 diabetes and obesity. The healthcare company said topline analysis of results demonstrated that OPK88003 met the primary objective with a statistically significant reduction of hemoglobin A1c (HbA1c) after 30 weeks of treatment versus a placebo. It also met a secondary goal of statistically significant weight loss. Shares of Miami-based OPKO gained 7% to $2.63 in Thursday’s Nasdaq trading. READ: OPKO Health sees prescriptions for Rayaldee triple in third quarter “We are pleased with the results of this trial, which show that OPK88003 has the potential to compete favorably with other drugs on the market or under development to treat Type 2 diabetes, obesity and related conditions,” OPKO Chairman and CEO Phillip Frost said in a statement. “We will now carefully evaluate strategic options for the design of Phase 3 trials and later, if successful, commercialization.” OPK88003-treated patients showed significant blood triglyceride decreases from baseline, according to OPKO. The company said it plans to present results at the American Diabetes Association meeting from June 7 to 11 in San Francisco. Contact Dennis Fitzgerald at email@example.com
Scientists from around the world convened in Orlando (USA) on March 31, 2019, at the Chemistry and Biological Effects of Maple Food Products symposium to share the recent results of their preliminary..
CHI Saint Joseph Health will host its 4th annual Diabetes and Nutrition Expo on Saturday, March 16 from 8:30 a.m. to 12:30 p.m. This expo is encouraged for people living with diabetes and those who may..
According to UPI, eating nuts may help people living with type 2 diabetes. A recent study found that type 2 diabetes patients who ate five servings of nuts per week had a lower risk for cardiovascular..